Abstract 236P
Background
Nasopharyngeal carcinoma is a disease unique to Southeast Asia. Radiotherapy and chemotherapy serve as the standard treatment mode for locally advanced nasopharyngeal carcinoma (LANPC), but the efficacy is not ideal due to local recurrence and distant metastasis. Meanwhile, studies have shown concurrent chemoradiotherapy will aggravate treatment-related side effects. Chrono-chemotherapy is to select the appropriate timing of administration according to the biological rhythm of the human body, in order to improve the efficacy and reduce side effects. At present, most studies on the treatment of LANPC by hourly chemotherapy combined with radiotherapy are single-center and small-sample studies, lacking evidence-based medical evidence. Therefore, we adopted the method of meta-analysis to evaluate the efficacy and safety of chemotherapy combined with radiotherapy for LANPC in existing studies, in order to provide reference for clinical treatment.
Methods
Seven databases were searched, including the Cochrane Library (Issue 5, 2021), Pubmed, Embase, CBM, CNKI, VIP and Wanfang Database. The meta-analysis was performed by the Revman 5.3 software.
Results
Thirteen studies containing 901 patients were finally included. Compared with the conventional chemotherapy group, results showed that the effective rate, adverse reactions and immune function of the chrono-chemotherapy group was significantly higher than that of the conventional chemotherapy group. Chrono-chemotherapy combined with radiotherapy can increase the effective rate (P<0.001), and the CD3, CD, CD4/CD8 were higher than the conventional chemotherapy group (P<0.001), at the same time, chrono-chemotherapy group cloud reduce the III-IV°leucopenia, thrombocytopenia, gastrointestinal reaction, oral mucosa reaction, radiothermitis (P<0.001).
Conclusions
Current evidence shows that compared with the conventional chemotherapy group, the chrono-chemotherapy with radiotherapy could improve the effective rate and immune function, and reduce adverse reactions at the same time.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract